In this article
4D Bioprinting for Enhanced Drug Hepatotoxicity Testing
Poietis worked with pharmaceutical company Servier to develop a 4D bioprinted liver model that can better predict the liver toxicity of drugs.
Hepatotoxicity testing is one of the key tests conducted during preclinical trials using study drugs. Bruno Brisson, co-founder of Poietis, said, “The role of the liver is to degrade substances that are toxic to the body into non-toxic products, but sometimes excessive toxicity can cause important liver lesions.” Animal models of human hepatocytes and cell culture are usually used To predict toxicity, but because they cannot fully replicate the processes that occur in the liver of a real human, their accuracy is limited.
Advancements in Laser-Assisted 3D Liver Models
Using Poietis’ bioprinting technology, you can better perform tests to predict liver toxicity. Using the company’s laser-assisted bioprinting technology, the liver model contains different types of human liver cells and immune cells, which can be distributed in three dimensions with high precision. Brisson further explained, “Most of the in vitro liver models used for drug analysis are generated using two-dimensional monolayer cell tissue, but this new three-dimensional model better simulates the complex liver multicellular tissue structure. Drug toxicity testing is of great significance. The model will be validated by testing a group of compounds that can or cannot induce liver toxicity. Brisson is expected to complete it within 18 months.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.